APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metastatic Prostate

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Metastatic Prostate Market Outlook and Growth Opportunities 2026

31 December 2025199 pages

Choose your research edition.

Industry ResearchMetastatic Prostate Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Metastatic Prostate Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Metastatic Prostate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metastatic Prostate Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Metastatic Prostate Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Metastatic Prostate market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Metastatic Prostate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metastatic Prostate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metastatic Prostate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Metastatic Prostate market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Metastatic Prostate market include Genentech, BeiGene, Amgen, Zenith Epigenetics Ltd., VasGene Therapeutics, Inc., Telix Pharmaceuticals, SeleXel, Myovant Biosciences and Immunomedics(Gilead Sciences, Inc.), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Metastatic Prostate market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metastatic Prostate and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metastatic Prostate revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Metastatic Prostate market.

Metastatic Prostate Segment by Company

Genentech

BeiGene

Amgen

Zenith Epigenetics Ltd.

VasGene Therapeutics, Inc.

Telix Pharmaceuticals

SeleXel

Myovant Biosciences

Immunomedics(Gilead Sciences, Inc.)

eFFECTOR Therapeutics

Arvinas Inc.

AB Science

Metastatic Prostate Segment by Type

Mono

Mono/Combination

Combination

Metastatic Prostate Segment by Application

Hospital

Drug Store

Online Pharmacy

Metastatic Prostate Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Metastatic Prostate status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Metastatic Prostate key companies, revenue, market share, and recent developments.

3. To split the Metastatic Prostate breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Metastatic Prostate market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Metastatic Prostate significant trends, drivers, influence factors in global and regions.

6. To analyze Metastatic Prostate competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Prostate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metastatic Prostate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Prostate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Metastatic Prostate industry.

Chapter 3: Detailed analysis of Metastatic Prostate company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Metastatic Prostate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Metastatic Prostate in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Metastatic Prostate Industry Trends Table 2. Metastatic Prostate Industry Drivers Table 3. Metastatic Prostate Industry Opportunities and Challenges Table 4. Metastatic Prostate Industry Restraints Table 5. Global Metastatic Prostate Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Metastatic Prostate Revenue Share by Company (2021-2026) Table 7. Global Metastatic Prostate Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Metastatic Prostate Key Company Manufacturing Base & Headquarters Table 9. Global Metastatic Prostate Company, Product Type & Application Table 10. Global Metastatic Prostate Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Metastatic Prostate by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Mono Table 15. Significant Companies of Mono/Combination Table 16. Significant Companies of Combination Table 17. Global Metastatic Prostate Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Metastatic Prostate Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Metastatic Prostate Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Metastatic Prostate Sales Value Share by Type (2021-2026) Table 21. Global Metastatic Prostate Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Drug Store Table 24. Significant Companies of Online Pharmacy Table 25. Global Metastatic Prostate Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Metastatic Prostate Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Metastatic Prostate Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Metastatic Prostate Sales Value Share by Application (2021-2026) Table 29. Global Metastatic Prostate Sales Value Share by Application (2027-2032) Table 30. Global Metastatic Prostate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Metastatic Prostate Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Metastatic Prostate Sales Value Share by Region (2021-2026) Table 33. Global Metastatic Prostate Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Metastatic Prostate Sales Value Share by Region (2027-2032) Table 35. Global Metastatic Prostate Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Metastatic Prostate Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Metastatic Prostate Sales Value Market Share by Country (2021-2026) Table 38. Global Metastatic Prostate Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Metastatic Prostate Sales Value Market Share by Country (2027-2032) Table 40. Genentech Company Information Table 41. Genentech Business Overview Table 42. Genentech Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Genentech Metastatic Prostate Product Portfolio Table 44. Genentech Recent Development Table 45. BeiGene Company Information Table 46. BeiGene Business Overview Table 47. BeiGene Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. BeiGene Metastatic Prostate Product Portfolio Table 49. BeiGene Recent Development Table 50. Amgen Company Information Table 51. Amgen Business Overview Table 52. Amgen Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Amgen Metastatic Prostate Product Portfolio Table 54. Amgen Recent Development Table 55. Zenith Epigenetics Ltd. Company Information Table 56. Zenith Epigenetics Ltd. Business Overview Table 57. Zenith Epigenetics Ltd. Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Zenith Epigenetics Ltd. Metastatic Prostate Product Portfolio Table 59. Zenith Epigenetics Ltd. Recent Development Table 60. VasGene Therapeutics, Inc. Company Information Table 61. VasGene Therapeutics, Inc. Business Overview Table 62. VasGene Therapeutics, Inc. Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. VasGene Therapeutics, Inc. Metastatic Prostate Product Portfolio Table 64. VasGene Therapeutics, Inc. Recent Development Table 65. Telix Pharmaceuticals Company Information Table 66. Telix Pharmaceuticals Business Overview Table 67. Telix Pharmaceuticals Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Telix Pharmaceuticals Metastatic Prostate Product Portfolio Table 69. Telix Pharmaceuticals Recent Development Table 70. SeleXel Company Information Table 71. SeleXel Business Overview Table 72. SeleXel Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. SeleXel Metastatic Prostate Product Portfolio Table 74. SeleXel Recent Development Table 75. Myovant Biosciences Company Information Table 76. Myovant Biosciences Business Overview Table 77. Myovant Biosciences Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Myovant Biosciences Metastatic Prostate Product Portfolio Table 79. Myovant Biosciences Recent Development Table 80. Immunomedics(Gilead Sciences, Inc.) Company Information Table 81. Immunomedics(Gilead Sciences, Inc.) Business Overview Table 82. Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Product Portfolio Table 84. Immunomedics(Gilead Sciences, Inc.) Recent Development Table 85. eFFECTOR Therapeutics Company Information Table 86. eFFECTOR Therapeutics Business Overview Table 87. eFFECTOR Therapeutics Metastatic Prostate Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. eFFECTOR Therapeutics Metastatic Prostate Product Portfolio Table 89. eFFECTOR Therapeutics Recent Development Table 90. Arvinas Inc. Company Information Table 91. Arvinas Inc. Business Overview Table 92. Arvinas Inc. Metastatic Prostate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Arvinas Inc. Metastatic Prostate Product Portfolio Table 94. Arvinas Inc. Recent Development Table 95. AB Science Company Information Table 96. AB Science Business Overview Table 97. AB Science Metastatic Prostate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. AB Science Metastatic Prostate Product Portfolio Table 99. AB Science Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Metastatic Prostate Product Image Figure 2. Global Metastatic Prostate Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metastatic Prostate Market Size (2021-2032) & (US$ Million) Figure 4. Global Metastatic Prostate Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Mono Image Figure 8. Mono/Combination Image Figure 9. Combination Image Figure 10. Global Metastatic Prostate Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Metastatic Prostate Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Metastatic Prostate Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Drug Store Image Figure 15. Online Pharmacy Image Figure 16. Global Metastatic Prostate Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Metastatic Prostate Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Metastatic Prostate Sales Value Share by Application (2021-2032) Figure 19. Global Metastatic Prostate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Metastatic Prostate Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Metastatic Prostate Sales Value (2021-2032) & (US$ Million) Figure 22. North America Metastatic Prostate Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Metastatic Prostate Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Metastatic Prostate Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Metastatic Prostate Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Metastatic Prostate Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Metastatic Prostate Sales Value (2021-2032) & (US$ Million) Figure 28. South America Metastatic Prostate Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Metastatic Prostate Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Metastatic Prostate Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Metastatic Prostate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Metastatic Prostate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Metastatic Prostate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Mono
  • Mono/Combination
  • Combination
Applications
  • Hospital
  • Drug Store
  • Online Pharmacy
Companies covered
  • Genentech
  • BeiGene
  • Amgen
  • Zenith Epigenetics Ltd.
  • VasGene Therapeutics, Inc.
  • Telix Pharmaceuticals
  • SeleXel
  • Myovant Biosciences
  • Immunomedics(Gilead Sciences, Inc.)
  • eFFECTOR Therapeutics
  • Arvinas Inc.
  • AB Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Metastatic Prostate Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Metastatic Prostate Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Metastatic Prostate Market Dynamics
  1. 2.1 Metastatic Prostate Industry Trends
  2. 2.2 Metastatic Prostate Industry Drivers
  3. 2.3 Metastatic Prostate Industry Opportunities and Challenges
  4. 2.4 Metastatic Prostate Industry Restraints
3 Metastatic Prostate Market by Company
  1. 3.1 Global Metastatic Prostate Company Revenue Ranking in 2025
  2. 3.2 Global Metastatic Prostate Revenue by Company (2021-2026)
  3. 3.3 Global Metastatic Prostate Company Ranking (2024-2026)
  4. 3.4 Global Metastatic Prostate Company Manufacturing Base and Headquarters
  5. 3.5 Global Metastatic Prostate Company Product Type and Application
  6. 3.6 Global Metastatic Prostate Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Metastatic Prostate Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Metastatic Prostate Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Metastatic Prostate Market by Type
  1. 4.1 Metastatic Prostate Type Introduction
  2. 4.1.1 Mono
  3. 4.1.2 Mono/Combination
  4. 4.1.3 Combination
  5. 4.2 Global Metastatic Prostate Sales Value by Type
  6. 4.2.1 Global Metastatic Prostate Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Metastatic Prostate Sales Value by Type (2021-2032)
  8. 4.2.3 Global Metastatic Prostate Sales Value Share by Type (2021-2032)
5 Metastatic Prostate Market by Application
  1. 5.1 Metastatic Prostate Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug Store
  4. 5.1.3 Online Pharmacy
  5. 5.2 Global Metastatic Prostate Sales Value by Application
  6. 5.2.1 Global Metastatic Prostate Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metastatic Prostate Sales Value by Application (2021-2032)
  8. 5.2.3 Global Metastatic Prostate Sales Value Share by Application (2021-2032)
6 Metastatic Prostate Regional Value Analysis
  1. 6.1 Global Metastatic Prostate Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metastatic Prostate Sales Value by Region (2021-2032)
  3. 6.2.1 Global Metastatic Prostate Sales Value by Region: 2021-2026
  4. 6.2.2 Global Metastatic Prostate Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Metastatic Prostate Sales Value (2021-2032)
  7. 6.3.2 North America Metastatic Prostate Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Metastatic Prostate Sales Value (2021-2032)
  10. 6.4.2 Europe Metastatic Prostate Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Metastatic Prostate Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Metastatic Prostate Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Metastatic Prostate Sales Value (2021-2032)
  16. 6.6.2 South America Metastatic Prostate Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Metastatic Prostate Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Metastatic Prostate Sales Value Share by Country, 2025 VS 2032
7 Metastatic Prostate Country-level Value Analysis
  1. 7.1 Global Metastatic Prostate Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Metastatic Prostate Sales Value by Country (2021-2032)
  3. 7.2.1 Global Metastatic Prostate Sales Value by Country (2021-2026)
  4. 7.2.2 Global Metastatic Prostate Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Metastatic Prostate Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Metastatic Prostate Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Metastatic Prostate Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Metastatic Prostate Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Metastatic Prostate Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Metastatic Prostate Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Metastatic Prostate Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Metastatic Prostate Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Metastatic Prostate Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Metastatic Prostate Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Metastatic Prostate Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Metastatic Prostate Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Metastatic Prostate Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Metastatic Prostate Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Metastatic Prostate Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Metastatic Prostate Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Metastatic Prostate Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Metastatic Prostate Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Metastatic Prostate Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Metastatic Prostate Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Metastatic Prostate Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Metastatic Prostate Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Metastatic Prostate Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Metastatic Prostate Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Metastatic Prostate Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Metastatic Prostate Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Metastatic Prostate Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Metastatic Prostate Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Metastatic Prostate Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Metastatic Prostate Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Genentech
  2. 8.1.1 Genentech Company Information
  3. 8.1.2 Genentech Business Overview
  4. 8.1.3 Genentech Metastatic Prostate Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Genentech Metastatic Prostate Product Portfolio
  6. 8.1.5 Genentech Recent Developments
  7. 8.2 BeiGene
  8. 8.2.1 BeiGene Company Information
  9. 8.2.2 BeiGene Business Overview
  10. 8.2.3 BeiGene Metastatic Prostate Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BeiGene Metastatic Prostate Product Portfolio
  12. 8.2.5 BeiGene Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Metastatic Prostate Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Metastatic Prostate Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Zenith Epigenetics Ltd.
  20. 8.4.1 Zenith Epigenetics Ltd. Company Information
  21. 8.4.2 Zenith Epigenetics Ltd. Business Overview
  22. 8.4.3 Zenith Epigenetics Ltd. Metastatic Prostate Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zenith Epigenetics Ltd. Metastatic Prostate Product Portfolio
  24. 8.4.5 Zenith Epigenetics Ltd. Recent Developments
  25. 8.5 VasGene Therapeutics, Inc.
  26. 8.5.1 VasGene Therapeutics, Inc. Company Information
  27. 8.5.2 VasGene Therapeutics, Inc. Business Overview
  28. 8.5.3 VasGene Therapeutics, Inc. Metastatic Prostate Revenue and Gross Margin (2021-2026)
  29. 8.5.4 VasGene Therapeutics, Inc. Metastatic Prostate Product Portfolio
  30. 8.5.5 VasGene Therapeutics, Inc. Recent Developments
  31. 8.6 Telix Pharmaceuticals
  32. 8.6.1 Telix Pharmaceuticals Company Information
  33. 8.6.2 Telix Pharmaceuticals Business Overview
  34. 8.6.3 Telix Pharmaceuticals Metastatic Prostate Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Telix Pharmaceuticals Metastatic Prostate Product Portfolio
  36. 8.6.5 Telix Pharmaceuticals Recent Developments
  37. 8.7 SeleXel
  38. 8.7.1 SeleXel Company Information
  39. 8.7.2 SeleXel Business Overview
  40. 8.7.3 SeleXel Metastatic Prostate Revenue and Gross Margin (2021-2026)
  41. 8.7.4 SeleXel Metastatic Prostate Product Portfolio
  42. 8.7.5 SeleXel Recent Developments
  43. 8.8 Myovant Biosciences
  44. 8.8.1 Myovant Biosciences Company Information
  45. 8.8.2 Myovant Biosciences Business Overview
  46. 8.8.3 Myovant Biosciences Metastatic Prostate Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Myovant Biosciences Metastatic Prostate Product Portfolio
  48. 8.8.5 Myovant Biosciences Recent Developments
  49. 8.9 Immunomedics(Gilead Sciences, Inc.)
  50. 8.9.1 Immunomedics(Gilead Sciences, Inc.) Company Information
  51. 8.9.2 Immunomedics(Gilead Sciences, Inc.) Business Overview
  52. 8.9.3 Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Product Portfolio
  54. 8.9.5 Immunomedics(Gilead Sciences, Inc.) Recent Developments
  55. 8.10 eFFECTOR Therapeutics
  56. 8.10.1 eFFECTOR Therapeutics Company Information
  57. 8.10.2 eFFECTOR Therapeutics Business Overview
  58. 8.10.3 eFFECTOR Therapeutics Metastatic Prostate Revenue and Gross Margin (2021-2026)
  59. 8.10.4 eFFECTOR Therapeutics Metastatic Prostate Product Portfolio
  60. 8.10.5 eFFECTOR Therapeutics Recent Developments
  61. 8.11 Arvinas Inc.
  62. 8.11.1 Arvinas Inc. Company Information
  63. 8.11.2 Arvinas Inc. Business Overview
  64. 8.11.3 Arvinas Inc. Metastatic Prostate Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Arvinas Inc. Metastatic Prostate Product Portfolio
  66. 8.11.5 Arvinas Inc. Recent Developments
  67. 8.12 AB Science
  68. 8.12.1 AB Science Company Information
  69. 8.12.2 AB Science Business Overview
  70. 8.12.3 AB Science Metastatic Prostate Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AB Science Metastatic Prostate Product Portfolio
  72. 8.12.5 AB Science Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst